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I. Introduction 
  On July 16, 2012, the FDA approved TRUVADA, the first drug approved to reduce the 
risk of HIV infection in uninfected individuals who are at high risk of HIV infection, such as 
those with an HIV-infected partner, or partners at high risk for HIV infection.1 Truvada for HIV 
pre-exposure prophylaxis has been shown to prevent the spread of HIV.2 However, significant 
risks exist if the drug recommendations are not properly adhered to which can lead to the spread 
of the HIV virus, as well as other diseases.3 This paper will first discuss a brief history of HIV 
medications and an introduction of how Pre=Exposure Prophylaxis (PrEP) was discovered, and 
what PrEP is. The paper will further discuss the TRUVADA Risk Evaluation and Mitigation 
Strategy (REMS) and the potential unintended consequences of the drug. The paper will then 
conclude with the best course of action that should be followed to address these consequences. 
 
Each new generation of doctors and scientists is faced with the challenge of new and 
emerging diseases. These doctors and scientists join teams of established men and women who 
have spent their lives tirelessly looking for discoveries to put an end to diseases that have taken 
                                                     
1Press Release, Gilead Sciences, Inc., U.S. Food and Drug Administration Approves Gilead’s 
Truvada for Reducing the Risk of Acquiring HIV (July 16, 2012) (on file with author). 
2 Id. 
3 Id. 
 
 
3 
the lives of many people. When a new drug is approved by the FDA and is shown to stop the 
spread of the disease, prescribers and patients may jump at the chance to use the drug, especially 
when they have lost all hope. Often, these prescribers and patients may utilize the treatments 
before the full risks associated with the medication are appreciated. 
II. Background 
In 1981, doctors reported a new disease among homosexual men in the United States.4 It 
would take four years before an antibody test was available to diagnose infection.5 In 1983, the 
World Health Organization started Global HIV surveillance and held its first meeting on AIDS.6  
It would be years before the government took any action to acknowledge the AIDS crisis.7 
President Ronald Reagan did not mention AIDS publicly until 1986 and when he finally did utter 
the word, he provided very limited funding.8 The significance of President Reagan’s delay in 
speaking about AIDS is that his delay may have led to the dearth of knowledge about the disease 
or what caused it, especially in groups at highest risk for infection, such as with men who have 
sex with men (MSM).9  Without society having the education or knowledge of HIV and its 
infectious potential, the disease spread and HIV infection rates soared. This remains relevant 
today because we continue to inadequately educate people on the dangers of unprotected sex.  
 
Advancement in the use of HIV medications has come a long way since the discovery of 
the HIV virus. Azidothymidine, or AZT, was the first medication approved for the treatment of 
                                                     
4  A Timeline of HIV/AIDS, http://www.AIDS.gov (last visited Nov. 12,2016).  
5 Id. 
6 Id. 
7 Id. 
8 Philip Boffey, Reagan Defends Financing For Aids, N.Y. Times, Sept. 18, 1985.  
9 Id. 
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HIV infection, in the 1980s.10 Care of HIV infected patients improved markedly when additional 
drugs were discovered, and the standard of care became use of several drugs in combination, a 
concept known as Highly Active Anti-Retroviral Therapy (HAART).11 This concept remains the 
cornerstone of HIV treatment today.12 In the subsequent years, physicians and scientists realized 
that HIV medications were effective in preventing HIV infection in patients who had been 
exposed to the virus.13 Post-Exposure Prophylaxis (PEP) for HIV was successful in preventing 
HIV infections in healthcare workers exposed to the virus through needle sticks.14 AZT is still 
the drug of choice for preventing perinatal HIV infection in the children of HIV-infected 
pregnant patients15. AZT is administered to the mother in several doses around the time of 
delivery, and is given to the newborn for the first 4-6 weeks of life. 16This is associated with an 
HIV transmission rate near zero, whereas HIV perinatal transmission occurs about in 25% of 
patients where there is no prophylaxis. 17 In recent years, HIV prevention guidelines 
recommended the use of PEP in nonoccupational HIV exposures18. Nonoccupational PEP 
                                                     
10 Samuel Broder, The Development of antiretroviral therapy and its impact on the HIV-1/AIDS 
pandemic, 85 Antiviral Research 1 (Jan. 2010).  
11 Stefano M. Bertozzi, The Evolving HIV/AIDS Response And The Urgent Tasks Ahead, 28 
Heath Affairs 1578-1590 (Nov. /Dec. 2009). 
12 Id. 
13 Id. 
14 Id. 
15 Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for 
Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, 
NIH.(Oct. 26, 2016). 
http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/peri_recommendations.pdf. 
16 Id. 
17 Id. 
18 Updated Guideline for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug 
Use, or Other Nonoccupational Exposure to HIV-United States, 2016, CDC. (2016), 
https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf. 
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(nPEP) is highly effective when a three drug regimen is started within 72 hours after a high risk 
exposure to the HIV virus, and continued for 28 days. 19 
Antiretroviral drugs are one of the most lifesaving discoveries in recent medicine, having 
saved millions of lives in patients infected with HIV, and have prevented countless potential 
infections in exposed patients20. In 2012, a new frontier emerged in HIV prevention when an 
existing HIV treatment was approved for use in HIV negative patients for the prevention of HIV 
infection.21 Truvada is a brand-name medication containing two antiretroviral medications, 
tenofovir and emtricitabine.22 Truvada was initially approved for the treatment of HIV infection 
in 2004 in combination with other medications.23 It is also a component of three drug regimens 
for HIV post exposure prophylaxis.24 Approval of Truvada for a pre-exposure prophylaxis is 
indeed life changing, and in some cases lifesaving, but it is vitally important that a greater effort 
be made to ensure that the drug is used safely.25 Modifications to how the drug is prescribed 
must be made to ensure that the drug is used safely and that patients are receiving the maximum 
benefit of the drug without the acquisition of unnecessary or unappreciated risk. 26 
  
 In 1987 the FDA approved the drug zidovudine (AZT).27 AZT was the first drug 
available to treat HIV but it had significant obstacles in the treatment of the HIV infection.28 The 
                                                     
19 Id. 
20 Antiretroviral drugs used in the treatment of HIV infection, FDA.gov. (Aug. 9, 2016), 
http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm 
21 Id. 
22 Id. 
23 Id. 
24 Id. 
25 Id. 
26 Id. 
27 See supra note 11. 
28 Id. 
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cost of the medication was extremely expensive and the medication had major toxicity.29 Even 
with the high costs and burden of side effects, the drug did not have a long survival benefit that 
outweighed the obstacles.30 
 Next, there was a development of a multi-drug therapy that was discovered to work better 
than AZT and this was considered one of the great success stories of modern medicine.31 It was 
discovered that the virus mutates and that a combination of drugs together would more 
effectively fight the disease.32 This combination of drugs (HAART) changed what was once a 
nearly universally fatal illness to a manageable chronic disease.33 
 TRUVADA was first approved by the FDA in August of 2004 as a safe and effective 
treatment for HIV.34 It was then discovered that individuals who take antiviral therapy shortly 
after exposure to HIV have a strong likelihood of avoiding infection.35  This is known as PEP 
(post-exposure prophylaxis), and if taken within 72 hours of exposure is highly effective.36 
 PrEP (Pre-exposure prophylaxis) was discovered based on the observation of monitoring 
how PEP worked.37  PEP is prescribed when someone is or believes that they are exposed to the 
HIV virus.38 The crucial aspect of the efficacy of PEP is the time from HIV exposure to the first 
dose of antiretroviral medication.39 The time between when someone was exposed to HIV and 
                                                     
29 Id. 
30 Id. 
31 Id. 
32 Id.  
33 Id. 
34 Takunda Matose, The Problems With Pre-Exposure HIV Prevention, Science Progress, Aug. 
13, 2012. 
35 Id. 
36 Id.  
37 Raphael J. Landovitz, MD, Preesposure Prophylaxis For HIV Prevention: What we Know and 
What We Still Need to Know for Implementation, 23 Top Antivir Med. 85, (2015). 
38 Id. 
39 Id. 
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the time they took PEP was essential in getting the maximum benefit of the drug.40 The closer 
the timeframe from exposure to medication approaches zero, the better chance the person has of 
not contracting the disease.41 
 
 PrEP is a means of using medications to prevent HIV infection in uninfected patients.42 
On July 16, 2012, the FDA approved a new indication for TRUVADA.43  It was now the first 
drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk 
of HIV infection and who may engage in sexual activity with HIV-infected partners.44  The 
approval of TRUVADA was postponed a month because of pressing ethical concerns with the 
drug.45 First, there was a concern that TRUVADA could encourage riskier behavior and 
potentially lead to higher rates of the HIV infection.46 Second, non-adherence to the strict dosing 
rules can lead to more virulent strains of the virus.47 Questions remain about whether the 
potential for non-adherence could cause more harm than the drug does good.48 
III. Truvada REMS 
 To address these serious ethical issues surrounding approval of TRUVADA for PrEP, the 
FDA required Gilead, the manufacturer of TRUVADA, to provide a risk evaluation and 
mitigation strategy (REMS).49 REMS provides important information about adherence and the 
                                                     
40 Id. 
41 Id.  
42 Truvada for PrEP Fact Sheet: Ensuring Safe and Proper Use. (2012), 
http://www.fda.gov/downloads/NewsEvents/Newsroom/FactSheets/UCM312279.pdf. 
43 Id. 
44 Id. 
45 Id. 
46 Id. 
47 Id. 
48 Id.  
49 See supra note 34. 
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risk of developing drug resistance.50 However, the REMS may not adequately address unrealistic 
expectations on the part of patients. 51 
 The Food and Drug Administration Amendments Act (FDAAA) clarified FDA’s 
authority to require enforceable risk management programs such as REMS.52 Section 505-1 of 
the FDAAA states when the FDA may require a REMS: “1) before approval: If the FDA 
determines a REMS is necessary to ensure that the benefits of the drug outweigh the risks. 2) 
Post approval: if the FDA becomes aware of new safety information and determining if REMS is 
necessary to ensure the benefits of the drug outweigh the risk.”53 An applicant is also permitted 
to voluntarily submit a proposed REMS if they believe it is necessary. 54There are many factors 
that the FDA must consider when determining the need for a REMS. They must consider, “1) the 
size of the population that is likely to use the drug. 2)the seriousness of the disease; 3) the 
expected benefit of the drug; 4) the expected duration of the treatment; 5) the seriousness of 
known or potential adverse events and 6) whether the drug is a new molecular entity.”55 
 
 The FDA determined that a REMS is necessary to ensure that the benefits of TRUVADA 
outweigh whatever risks it may impose.56 PrEP was approved with a risk evaluation and 
mitigation strategy (REMS) to minimize the risk to uninfected individuals of acquiring HIV 
                                                     
50 Id. 
51 Id. 
52 Lena Y. Choe, Risk Evaluation and Mitigation Strategies (REMS), 
http://www.fda.gov/downloads/AboutFDA/WorkingatFDA/FellowshipInternshipGraduateFacult
yPrograms/PharmacyStudentExperientialProgramCDER/UCM276838.pdf. 
53 Id. 
54 Id. 
55 Id. 
56 Truvada for PrEP Fact Sheet: Ensuring Safe and Proper Use. (2012), 
http://www.fda.gov/downloads/NewsEvents/Newsroom/FactSheets/UCM312279.pdf. 
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infection and to reduce the risk of development of resistant HIV-1 variants.57 The core 
component of the TRUVADA REMS is a training and educational program to assist prescribers 
in counseling individuals who are taking or considering TRUVADA for PrEP.58 The goals of 
the REMS for TRUVADA as a PrEP indication are: 
To inform and educate prescribers and uninfected 
individuals at high risk for acquiring HIV-1 infection about: the 
importance of strict adherence to the recommended dosing 
regimen. The importance of regular monitoring of HIV-1 
serostatus to avoid continuing to take TRUVADA for a PrEP 
indication, if seroconversion has occurred, to reduce the risk of 
development of resistant HIV-1 variants. The fact that TRUVADA 
for a PrEP indication must be considered as only a part of a 
comprehensive prevention strategy in order to reduce the risk of 
HIV-1 infection and that other preventive measures should also be 
used.59 
 
The first and most important goal of the REMS is to inform patients of the critical need 
for strict adherence to the recommended dosing regimen.60  Patients must be instructed that daily 
dosing must be maintained or the patient will not receive the maximum benefits of the drug.61 
The second goal is to ensure that patients are continuously being re-tested to make sure that they 
continue to test negative. 
 The importance of regular monitoring of HIV-1 serostatus to 
avoid continuing to take TRUVADA for a PrEP indication, if 
seroconversion has occurred, to reduce the risk of development of 
resistant HIV-1 variants.  “A negative HIV-1 test must be 
confirmed immediately before starting TRUVADA for a PrEP. 
indication and reconfirmed during treatment. Drug resistant HIV-1 
variants have been identified with the use of TRUVADA for a 
PrEP  indication following uninfected HIV-1 infection.62 
                                                     
57 Id. 
58 Id. 
59 TRUVADA REMS. (last visited Dec. 1, 2016) www.gilead.com  
60 Id. 
61 Id. 
62 Id. 
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  It is important to note that monotherapy with TRUVADA is only adequate for pre-
exposure prophylaxis in an HIV uninfected patient.63 The two drugs in Truvada, when taken 
alone, are not effective for the treatment of HIV.64 Current standards recommend a three-drug 
regimen for HIV treatment.65 Using fewer than three drugs for the treatment of HIV has been 
shown to lead to inadequate suppression of the virus and has been associated with the 
development of drug-resistant strains of HIV.66 Since the drugs contained in Truvada are also 
core components in many regimens for HIV treatment, drug resistance to one or both of these 
medications would significantly limit the treatment options available to a newly infected 
patient.67  It is essential that a patient know their HIV status during the entire duration of 
treatment with PrEP for HIV prevention.68 If the patient ever has a confirmed positive result, 
they must discontinue PrEP and begin treatment for the disease.69 
The REMS for Truvada consists of a training guide for healthcare providers which has 
prescribing considerations such as, 
Only prescribe TRUVADA as a comprehensive prevention 
strategy…counsel all uninfected individuals to strictly adhere to 
their TRUVADA daily dosing schedule…confirm a negative HIV-
1 test immediately prior to initiating TRUVADA for a PrEP 
indication…screen uninfected individuals for HIV-1 infection at 
least one every 3 months…do not prescribe TRUVADA for PrEP 
indication if signs or symptoms of acute HIV infection are 
present.70 
                                                     
63 See supra note 34. 
64 Id. 
65 Id. 
66 Id. 
67 Id. 
68 Id. 
69 Id. 
70 Training Guide for Healthcare Providers. (2016). 
http://www.truvadapreprems.com/Content/pdf/Training_Guide_for_Healthcare_Providers.pdf 
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There is also a safety guide for patients.71 The guide informs patients that they should 
make sure that they are HIV negative and stay negative while on PrEP.72  One section of the 
guide reads “Just taking Truvada alone may not keep you from getting HIV-1 infection…You 
must continue using safer sex practices while you are taking TRUVADA to reduce your risk of 
getting HIV-1 infection.” 73 Interestingly, the word “condom” does not appear anywhere in this 
safety guide. It is making the assumption that 1) Patients will actually read this guide, and 2) 
That patients that do read the guide are capable to understand that condoms are being implied by 
the phrase “using safer sex practices.”74   
 
IV. Barriers to Access 
There are barriers to accessing PrEP that can create obstacles to patients who may benefit 
from the drug.75 The first major barrier is that people who can benefit from the drug are not 
receiving it because they may not even know that it exists.76 Accessibility is a barrier to PrEP 
because it is a prescription only medication, and obtaining it requires a patient-provider 
discussion about patients’ sexual behaviors and level of risk.77 Those who may know it exists 
may not feel comfortable discussing their sexual activity in front of doctors.78 “In a recent survey 
                                                     
71 Id. 
72 Id. 
73 Id. 
74 Id. 
75 Joseph Schwartz and Josh Grimm, PrEP on Twitter: Information, Barriers, and Stigma, 
Health Communication. (Jun. 13, 2016) 
76 Id. 
77 Id. 
78 James Wilton, Pre-Exposure prophylaxis for sexually-acquired HIV risk management: a 
review 7 HIV/AIDS- Research and Palliative Care 125 (April 28, 2015). 
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of over 9,000 MSM in the US, 16% did not have a primary care provider and only half of those 
with a provider felt comfortable talking to them about sex.”79  If patients do not have a primary 
doctor that they see on a regular basis then they are less likely to feel comfortable to confide in a 
perfect stranger.80 Patients in greatest need of PrEP may feel uncomfortable to discuss sexuality, 
let alone discuss their homosexuality and specific sexual behaviors which may place them at 
highest risk. 81 
Other patients may avoid getting PrEP because there is a stigma in regards to any type of 
HIV medication.82 PrEP may be associated with the stigma because people may believe that 
PrEP users are HIV infected.83 There is a stigma that if someone is using PrEP they are 
promiscuous or irresponsible.84 There are cultural and moral beliefs that someone that is using 
any type of HIV drug either has HIV or they are at high risk of being infected.85 Furthermore, 
“Prep may have generated ‘moral panic’ in certain stakeholders concerned about a potential loss 
of sexual restraints, leading to so-called risk compensation (i.e. having riskier sex and thereby 
neutralizing the benefit of prep).86 Even with the gay community, this concern has created a 
certain stigma affecting prep.”87  
                                                     
79 Id. 
80 Id. 
81 Id. 
82 Jeremy Sugarman, MD, Ethics and Pre-Exposure Prophylaxis for HIV-infection 63 J Acquir 
Immune Defic SSYndr. S135 (Jul. 2013). 
83 Id. 
84 Id. 
85 Id. 
86 Carlos F. Caceres, The Promises and challenges of pre-exposure prophylaxis as part of the 
emerging paradigm of combination HIV prevention, 18 J Int. AIDS Soc. (July 20, 2015). 
87 Id. 
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Another issue of concern for MSM patients is the stigma of receptive sex.88 There is a 
stigma that men who are the receptive partner are feminine and often these individuals may be 
reluctant to be honest about their sexual role out of shame or embarrassment.89 This is critically 
relevant to HIV prevention, because the risk of being infected with HIV is substantially higher 
for the receptive partner in MSM relationships.90  Being an insertive partner is ten times less 
risky than being a receptive partner.91  There is a 1 in 500 chance of becoming infected from one 
incident of unprotected anal sex with an HIV positive receptive partner, but there is a 1 in 50 
chance of becoming infected from one incident of unprotected anal sex with an HIV positive 
insertive partner.92 Since men who engage in receptive sex are more at risk of contracting HIV, 
they should be the first to take advantage of PrEP.93 Yet, this group of MSM may be less likely 
to ask their doctor about the drug for fear of being judged for their preferred sexual position.94 
About 14% of the more than 1.2 million Americans living with HIV are unaware of their 
status.95 For young people the numbers are more troubling.96 More than half of HIV-infected 
people age 13 to 24 are unaware of their status.97  The large number of cases that are 
undiagnosed or diagnosed at, an advanced state, represent lost opportunity for prevention and 
                                                     
88 B. Varghese, Reducing the risk of sexual hiv transmission quantifying the per-act risk for HIV 
on the basis of choice of partner, sex act, and condom use, 29 Sexually Transmitted Diseases. 38 
(2002). 
89 Id. 
90 Id. 
91 Id. 
92 Id. 
93 Id. 
94 Id. 
95 Lawrence O. Gostin and Lindsay F. Wilay, Public Health Law: Power, Duty, Restraint 369-
370 (Univ. of Cali. Press, 3rd ed. 2016). 
96 Id. 
97 Id. 
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treatment.98 Over time, however, it became clear that stigma and discrimination, which deter 
people from getting tested and seeking treatment were significant barriers to an effective public 
health response.99 In 2001 the United Nations called on states to enact law to eliminate all forms 
of discrimination against, and to ensure the full enjoyment of all human rights and fundamental 
freedoms by people living with HIV/AIDS and members of vulnerable group.100 
Destigmatization has the dual purpose of safeguarding individual rights and protecting the 
public’s health by reducing transmission.101 
 
Provider-level barriers include a lack of PrEP awareness and knowledge.102 Often, 
patients go to their primary care doctor for advice on medical conditions or to seek treatment for 
an unknown illness.103 Unfortunately, most generalists, even in urban areas with high HIV 
prevalence, are the least uninformed about the availability and use of PrEP.104 HIV specialists 
have the most experience and knowledge about PrEP but often patients do not seek out an HIV 
specialist.105 There may be a stigma that if an individual seeks out an HIV specialist that people 
will think that they have HIV.106 They will avoid these specialists who have the most knowledge 
about the medication and who would be better educated at discussing the requirements of 
                                                     
98 Id. 
99 Id. at 381. 
100 Id. at 383. 
101 Id. at 383. 
102 See supra note 71. 
103 See supra note 71. 
104 See supra note 71. 
105 See supra note 71. 
106 See supra note 71.  
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receiving the maximum benefit from the drug.107 Furthermore, those patients who are unfamiliar 
with PrEP would not know to seek out a specialist, even if they were motivated to do so.108 
A survey was developed to evaluate the current practices and attitudes among infectious 
disease experts. 109 The main purpose of this survey was to access provider opinions, readiness 
and current practices of PrEP in the United States and Canada.110 Questions included the 
physician’s HIV practice, whom they provided or would provide PrEP to, how they assess 
eligibility, how they measure adherence, when they would discontinue PrEP, and what perceived 
barriers exist.111. Nearly 75% of those physicians that responded supported the provision of PrEP 
but only 9% of those physicians actually provided PrEP to patients.112 Most physicians stated 
that they did not provide PrEP because they were worried about adherence and the risk for future 
resistance. 113 There was a concern from these doctors that there was a lack of resources and 
information and that they don’t know enough to feel comfortable enough to prescribe the 
medication.114 When doctors were asked to rank the order of barriers to prescribing PrEP, many 
stated that it was too time consuming to counsel and access adherence.115 
                                                     
107 See supra note 71. 
108 See supra note 71. 
109 Maile Y. Karris, Are we prepped for preexposure prophylaxis (Prep)? Provider Opinions on 
the Real-World Use of PrEP in the United States and Canada 58 Clinical Infectious Diseases 
704 (Dec. 6, 2013).  
110 Id. 
111 Id. 
112 Id. 
113 Id. 
114 Id. 
115 Id. 
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Another barrier to access is financial coverage for the medication.116 The high cost of the 
medication can pose a significant hardship on the individual and some may even think the cost is 
not worthwhile.117 The issue with this barrier is, even when patients have prescription coverage 
for the medication, navigating the requirements to get approval for the medication is time 
consuming.118 It is often difficult to get approval and this can be very discouraging for many 
patients.119 There is a paradox where uninsured patients could access PrEP through patient 
assistance programs but patients who are insured do not have access to the program because only 
uninsured qualify.120 Though these patients may have medical insurance, they cannot afford the 
medication because of the high cost of the deductible.121 There is also a concern that because 
follow-ups and monitoring are required they won’t be able to afford the frequent co-pays for the 
doctor visits, testing and refills.122 Financial constraints could also be a barrier to implanting 
PrEP in government funded or subsidized health systems.123 
V. Adherence Concerns 
Another issue is that some people who are receiving PrEP are not using it correctly.124 
There is a strong concern about adherence.125  Adherence was strong among patients who 
                                                     
116 Sarah K. Calabrese, Putting PrEP into Practice: Lessons learned from Early-Adopting U.S. 
Providers’ Firsthand Experiences Providing HIV Pre-Exposure Prophylaxis and Associated 
Care 11 PLOS one (June 15, 2016).  
117 Id. 
118 Id. 
119 Id. 
120 Id. 
121 Id. 
122 Id.  
123 Id.  
124 Douglas S. Krakower & Kenneth H. Mayer, Pre-Exposure Prophylaxis to Prevent HIV 
Infection: Current Status, Future Opportunities and Challenges 75 Drugs 243 (Feb. 2015). 
125 Id. 
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actively sought PrEP.126 These patients researched what PrEP was and how it could change their 
lives or they knew of friends or family who told them about the drug and its benefits.127 Many 
patients cite condom use as a barrier to physical intimacy and sexual pleasure.128 Patients who 
sought out PrEP on their own initiative were more likely to diligently use condoms and were 
motivated to seek a suitable alternative were much more responsible in adhering to the 
requirements of treatment.129 Alternatively, patients who started prophylaxis at the 
recommendation of their doctors tended to be less adherent.130 In fact, some of these patients 
were overwhelmed by the follow-ups that were required and often did not return.131  
  
Adherence among one of the target demographics for PrEP, young MSM, was most 
concerning.132 Most patients under the age of 25 have a limited degree of routine; they often do 
not do the same thing every day.133 This particular demographic is specifically unfamiliar with a 
daily regimen of medications accompanied by relatively frequent doctor visits.  134 
Another barrier is the anticipated behavior (risk compensation). 
This concern is best explained by the prevailing theory 
about how individuals manage their personal risks. Risk 
“homeostasis” is defined as “a system in which individuals accept 
a certain level of subjectively estimated (or “perceived”) risk to 
their health in exchange for benefits they expect to receive from an 
activity” In accepting a particular level of risk for an adverse event, 
individuals maintain an approximate risk set point. However, 
introduction of an intervention that reduces the perceived risk of 
                                                     
126 Id. 
127 Id. 
128 Id. 
129 Id. 
130 Id. 
131 Id.  
132 See supra note 109. 
133 See supra note 109. 
134 See supra note 109. 
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the behavior or activity may cause a person to increase risky 
behavior- this is called “risk compensation” so that the discrepancy 
between the level of risk he or she takes and the perceived risk 
increases.135 
 
In a study regarding ART (formally known as HAART), it was found that people who 
believed ART reduced the likelihood of HIV transmission or “lessened the likelihood of 
transmission were more likely to engage in unprotected sex.”136 With this information it would 
seem plausible that people would have the same feelings about PrEP.137 Prior to the FDA 
approval of PrEP, potential users were surveyed and reported that they believed taking PrEP 
could decrease their use of condoms.138 But risk compensation after PrEP implementation has 
been examined in several trials and to date has not been associated with increased sexual risk 
behavior or sexually transmitted infections in the majority of these studies.139 However, this may 
not be true in clinical practice; “all randomized and open-label trials of PrEP have provided and 
emphasized the use of condoms, as well as HIV testing: this model may not be fully 
implemented in clinical practice…sexual risk behaviors have been shown to increase following 
significant HIV biomedical breakthroughs.”140 
There is a misconception that PrEP is all that is needed to prevent the HIV virus when 
engaged in sexual activity.141  In a recent study on the use of PrEP, 30% of men reported that 
they would not use condoms or they would use condoms less often if they were on PrEP.142 One 
                                                     
135 Jill Blumenthal & Richard Haubrect, Risk compensation in PrEP: An old debate emerges yet 
again. 16 AMA Journal of Ethics (Nov. 2014).  
136 Id. 
137 Id. 
138 Id. 
139 Id. 
140 Id. 
141 Colleen C. Hoff, PhD, Attitudes Towards PrEP and Anticipated Condom Use Among 
Discordant Male Couples, 29 Aids Patient Care and STDs 408 (June 9, 2015). 
142 Id. 
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MSM in the study said, “If I were using it, I would assume I wouldn’t have to use a condom.”143 
The use of condoms is essential in combination with the drug to receive the highest level of the 
benefit of the medication.144 Though PrEP may help decrease the spread of the HIV infection, it 
does not stop the spread of other sexually transmitted diseases The CDC reported, 
Trend data shows the rate of syphilis are increasing at an alarming 
rate (15.1 percent in 2014). While rates have increased among both 
men and women, men account for more than 90 percent of all 
primary and secondary syphilis cases. Men who have sex with men 
(MSM) account for 83 percent of male cases where the sex of the 
partner is known. Primary and secondary syphilis are the most 
infections stages of the disease, and if not adequately treated, can 
lead to long-term infection which can cause visual impairment and 
stroke.145 
 
One reason that has been given to why sexually transmitted diseases is on the rise is 
because the change in behavior among gay and bisexual men and it correlates with the advent of 
HIV treatment.146 PrEP has changed what people think of HIV. Individual outlooks on the 
disease have changed considerably, but maybe to their detriment.147  Dr. Gail Bolan from the 
CDC was interviewed by NBC news and stated, “People are excited about it, and some have 
stopped using condoms so consistently, because they are no longer afraid of a deadly 
infection.148 But, unfortunately, HIV treatment has no impact on prevention of other STDs. 
unless you are using condoms consistently and correctly, you are putting yourself at risk for 
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STDs.”149 The 2015 CDC fact sheet shows that since 2014 Chlamydia is up 6%, Gonorrhea is up 
13%, Syphilis (primary and secondary) is up 19% and congenital syphilis is up 6%.150 
Even though adherence to the strict dosing is essential, condom use must still be adhered 
to. The problem lies with patients who believe as long as they adhere to the dosing requirements 
they do not need to use condoms.  
Initial data from demonstration studies in MSM show that 
people who choose to take PrEP may, in fact, be those who report 
episodes of unprotected anal intercourse, and their reported PrEP 
adherence is already high, with no subsequent risk compensation 
of change from their present condom use. Hence, at least among 
MSM, PrEP may become a choice among people at risk due to 
condomless anal sex, who feel that a daily pill may suit them better 
than condoms.151  
 
The presumption that condoms are unnecessary while taking PrEP is critically flawed.152 
Pre-exposure prophylaxis with TRUVADA alone does not confer 100% protection from HIV 
infection.153 It is essential that condoms are used in combination with the medication. “PrEP was 
misunderstood as intended to replace condoms, while in fact it was meant to become one element 
(but never the sole element) of the emerging paradigm of combination prevention.154  
David Knox, MD recently reported a case study at the 2016 Conference on Retroviruses 
and Opportunistic Infections (CROI) of a 43-year-old MSM with excellent adherence to the 
medication who tested positive for HIV after 2 years of treatment with PrEP.155 The patient’s 
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adherence was confirmed with pharmacy dispensing records, as well as blood tests for levels of 
the medication.156 Despite this excellent adherence and adequate drug levels in the body, he still 
contracted the HIV infection.157 This was the first reported case of HIV infection with evidence 
of long-term adherence to PrEP, but it would not be only case.158 In October of 2016, researchers 
at the 2016 HIV research for Prevention Conference made an announcement that a second man 
in the Unites States acquired HIV despite that he also was using PrEP.159 Dr. Howard Grossman, 
a New York City Physician, says that the man is his patient and was adhering to the PrEP dosing 
requirements since 2015.160 Dr. Grossman stated in an interview that “the man had required a 
rare strain of HIV that is resistant to both of the drugs found in TRUVADA.”161 Dr. Knox’s 
patient similarly acquired a strain of HIV resistant to both medications in TRUVADA.162 
Drug resistance is a particular concern if a patient is not consistently tested every three 
months.163 There is a concern that if a person continues to take PrEP when they are already 
infected, resistance to the medication may develop, “the box warning for tenofovir-emtricitabine, 
includes cautionary language regarding the need to ensure that those using the product for prep 
are HIV-uninfected before initiating use and they are regularly tested.”164  The current labeling 
for TRUVADA does not have a warning label in regards to adherence or using safer sex 
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practices.165 Without clear and simple instructions on how to take their medicines, these patients 
are subjected to medication errors that may lead to poor adherence and sub-therapeutic 
outcomes.166 Complexity of written information hinders patients’ understanding of their 
medications which then leads to misuse of prescribed medications.167  
One way to enhance patient understanding would be to develop patient warning labels. 
Prescription warning labels (PWLs) are small, colorful stickers adjacent to the prescription label 
on dispensing bottles that remind or highlight the most important instructions for patient’s safe 
and effective use of medications.168 For example, PWL’s contain warning statements about 
specified medications such as “do not take with alcohol: or “take with food.”169  Including the 
word “WARNING” creates alertness. Patients expressed that the word “WARNING” drew their 
attention to the PWL and it made them think of the cautionary instruction.170  Similar, pictorial 
warning labels were suggested on cigarette packs to convince people that smoking was bad for 
their health.171   Requiring pictorial warning labels on all cigarette packs would be appropriate 
for the protection of the public health because it would substantially reduce smoking prevalence 
and thereby reduce SADs and the morbidity and medical costs associated with adverse smoking-
attributable birth outcomes.172 In 2009, the Family Smoking Prevention and Tobacco Control Act 
was signed into law, authorizing the FDA to regulate cigarettes and other tobacco products, 
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including their packaging and labeling. 173 The D.C. Circuit Court of Appeals struck down the 
rule and hinged in part on a concern that the pictorial warning labels might not produce any 
significant reduction in smoking. 174 With recent studies on the effect of PWLS on prescription 
drugs there should be more of a warning on TRUVADA bottles and packaging.  
 
Another barrier is that young people are engaging in sexual activity at a much younger 
age and are often not educated on proper safer practices. 
According to the Center for Disease Control, almost half of U.S. 
high schoolers (46 percent) have had sexual intercourse, with 
approximately 6 percent having an age of sexual initiation as 
young as 13 years old. That means for the first few years a person 
is at the highest risk for acquiring HIV, they aren’t eligible for 
Truvada Prep per the FDA approval…we see that these are also the 
groups with the greatest risk factors for non-adherence.175 
 
The most important risk of this medication is that some MSMs will continue to believe 
that PrEP is all that is needed to not get infected with HIV.176 Numerous casual dating sites such 
as Manhunt, ADAM4ADAM and phone applications like GRINDR that make casual sex easier 
than ever.177 Looking through these sites, one quickly finds an enormity of profiles that in search 
of condomless sex: “bareback only – HIV negative on PREP.”178 These profiles make the 
mistaken claim that bareback (unprotected) sex is safe, provided one party is on PrEP. 179 These 
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individuals are mistakenly reassured in their immunity to HIV, not to mention their heightened 
risk for other sexually transmitted infections.180 This is a problem that may see astronomical 
destruction, especially among the gay population. 181 
According to the study, Zero feet away Perspective on HIV/AIDS and unprotected sex in 
men who have sex with men utilizing location based mobile Apps, a total 727 participants were 
recruited through advertisements placed on large geo-social networking apps for MSM 
responded to questionnaires about unprotected sex182. Nearly 50 % of the men surveyed said they 
are afraid of getting infected or re-infected with the virus, yet they persist to participate in risky 
taking activities such as unprotected anal intercourse. An astounding 46 % admitted to never 
using condoms. 183  
 
There are also concerns that the medication has some potential side effects which may 
cause patients to stop taking the medication as prescribed.184  Toxicity is a problem associated 
with the medication.185 The medication, in a small number of patients, has caused kidney and 
liver issues. “PrEP can cause decreases in kidney and liver function and bone mineral density, 
promisingly, renal function tended to return to normal after discontinuation of PrEP.”186 The 
problem with this is that the medication has to be stopped in order for the renal function to 
normalize but PrEP has a strict dosing requirement; it is not meant to be discontinued.187 
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V. Possible Solutions 
 
  
 Education for both the provider, as well as the patient is key is to addressing some of the 
potential barriers. Provider-level barriers include a lack of PrEP awareness and knowledge, as 
well as negative opinions and attitudes toward PrEP. 188 The first step is to increase the 
awareness and knowledge of the benefits of PrEP among at risk populations and service 
providers.189 Adherence is critical to reduce HIV infections.190 
If the public is not educated, there will be another epidemic that can sweep in.  The 
Syphilis outbreak in the 1930’s was a huge epidemic that was fueled by stigma surrounding 
testing and a concern that treatment would increase sexual risk behaviors.191 Practitioners need to 
make sure that patients seeking PrEP are not stigmatized in the same way that patients in the 
1930’s were stigmatized regarding syphilis.192 
 
 
There needs to be formal training and educational seminars so that prescribers are fully 
trained in effectively treating at risk patients about the use of PrEP. Currently, there is no formal 
training for prescribers or patients.193 “Nearly all providers indicated that they were self-educated 
with respect to PrEP. Rather than participating in formal training, their knowledge about PrEP 
was obtained through a combination of reading relevant literature, attending professional talks 
and conferences, consulting with colleagues.”194 
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The New York State Department of Health Aids Institute produced a Guidance of Pre-
Exposure Prophylaxis to Prevent HIV Transmission on what appropriate protocols should be 
followed to receive the maximum benefits of PrEP.195 They suggest to first screen the patient to 
ensure they are a candidate for the medication196. Next is to educate patient on how PrEP works, 
including its risks and benefits197. They emphasize that strict adherence is needed to maintain 
protective drug levels.198 Next, it is imperative that a negative test result is confirmed before 
PrEP is prescribed.199 The guidelines then suggest that once PrEP is prescribed to have the 
patient follow up in two weeks to assess possible side effects200. Then the patient should visit 
every three months for another HIV test to make sure that the patient is still testing negative and 
also assess kidney function and screen for other STIs. It is very important that there is follow-up 
management and monitoring. Prescribers should not only test the patient every three months for 
HIV infection and other STIs, but should also discuss prevention services such as risk reduction 
counseling and access to condoms.201  
Before HIV was discovered, in the 1970’s and 1980’s gay men had a sexual freedom to 
do what they wanted, where they wanted and with whomever they wanted. Sex was happening in 
a variety of different places. 
Establishments including certain bars, clubs and bathhouses 
which are used as places for engaging in high risk sexual activities 
contribute to the propagation and spread of such AIDS-associated 
retro-virus; Appropriate public health interventions to discontinue 
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such exposure at such establishments is essential to interrupting the 
epidemic among the people of the State of New York. 202 
 
Bathhouses were closed down due to the public health concern of widespread HIV 
infection at these establishments.203 This lead to the spread of the virus because men would meet 
up at these establishments and have unprotected sex because they were not aware of the 
consequences204. With PrEP, again MSM are not aware of the consequences.205  There is a new 
sexual liberation among gay men who believe that they can do what they want without protection 
and there are no consequences to having unprotected sex.206 In the 1970’s no one knew what 
HIV was, what AIDS was.207 No one knew that there was this horrendous disease that would kill 
millions of people.208 In 2015 there were 17 million people living with HIV who were on 
antiretroviral therapy.209 There were 2.1 million new HIV infections. In 2014 there were 390,000 
Tuberculosis-related AIDS deaths. In 2015 there were 36.7 million people worldwide living with 
HIV. there were 1.1million AIDS related deaths.210 Since the beginning of the epidemic, 78 
million people have contracted HIV and 35 million have died of AIDS-related causes. 211 
Without condom use there is a chance of individuals contracting HIV and any of the many other 
sexually transmitted diseases that can cause death. 
Deaths from sexually transmitted diseases (STDs) often 
occur long after acute infection, making their incidence difficult to 
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estimate. Some infections, such as syphilis, may directly result in 
death. By contrast, human papilloma virus (HPV), HIV, and 
hepatitis more commonly cause death because of secondary 
sequelae. Genital herpes, gonorrheal infection, and chlamydial 
infection may cause death from primary infection. 212 
 
  
 
 The safety guidelines part of the REMS need to be modified.213  There is not one place in 
the REMS guidelines where the word condom appears.214 The guidelines should be clearer and 
say, “You must still use condoms while on this medication.” If people are fully aware that they 
must still use condoms with this medication, some might choose to forgo the medication and just 
use condoms.215 
The REMS are merely suggestions. 216The REMS say “Uninfected individuals SHOULD 
be counseled about safer sex practices…SHOULD be tested to confirm they are HIV-1 
negative…SHOULD be screened at least every 3 months for HIV-1 status.”217  These guidelines 
only use the word “should,” it is a suggestion, meaning that they are able to deter from this 
guideline. These guidelines should be a “must.” If prescribers are able to deter from these 
guidelines, then patients and prescribers need to know what the consequences are if they do not 
adhere to these recommendations.  HIV testing is mandatory in the United States for blood and 
organ donors, military applicants and sometimes federal and state prisons.218  
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HIV- testing should be mandatory for anyone that is being prescribed PrEP. Testing 
should continue to be mandatory on a regular basis to make sure they are continuously being 
monitored to ensure they are not taking the medication while already have the virus.  Perhaps 
there should be some type of mandatory computer system or registry to verify and confirm 
repeated testing results. New York State currently uses this type of system for prescription 
monitoring program for certain controlled substances.219 Prescribers are required to consult the 
prescription monitoring program, known as I-Stop when prescribing controlled substances to 
determine whether prescription have been obtained elsewhere.220 Prescribers of PrEP could have 
a similar system where they must consult with a registry to make sure that when prescribing 
PrEP initial or as a refill, a patient is being retested for HIV. 
Another possible solution is more research is needed to see why adherence is such a 
problem and how to decrease the stigma in associated with PrEP.  Destigmatization is very 
important in order for patients to feel more comfortable is seeking out the drug.  In 2001 the 
United Nations called on states to enact law to eliminate all forms of discrimination against, and 
to ensure the full enjoyment of all human rights and fundamental freedoms by people living with 
HIV/AIDS and members of vulnerable group. 221 
  In spite of being described as a miracle, employing the drug Truvada as PrEP remains a 
highly contested and often stigmatized solution for prevention.222 Studying messages about PrEP 
on Twitter is valuable because it allows for a unique opportunity to explore how individuals 
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discussed PrEP.223 This is helpful to health professionals interested in understanding how to 
better address PrEP related stigma and how to reduce barriers to PrEP adoption.224  Stigmas and 
barriers to PrEP over the course of the history of AIDS in the US, significant portion of the 
American population reported feeling anger, disgust, fear, and blame toward people with 
AIDS.225 HIV-related stigmatization continues to occur because of the implication that PrEP will 
encourage people to abandon the safer sex practices, some MSM who take it report they were 
stigmatized by their medical provides, friends and sex partners.226 Huffington Post columnist 
David Duran referred to gay0 men on PrEP as “Truvada whores” because they might engage in 
condomless intercourse.227 In a widely cited Associated Press article, the President of the AIDS 
Healthcare foundation, Michael Weinstein described PrEP as a party drug.228 
 
 
VI. Conclusion. 
 
 
Randomized placebo-controlled studies have demonstrated that daily oral anti-retroviral 
pre-exposure chemoprophylaxis (PrEP) can significantly reduce HIV incidence among diverse 
at-risk populations.229 In these studies, the efficacy of PrEP was correlated with levels of 
adherence.230 These challenges include low awareness and utilization of PrEP by high risks 
persons, uncertainty about the drug. However, several potential barriers to implementing PrEP 
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remain. These include low awareness and utilization of PrEP by at-risk persons, uncertainty 
about adherence in real world settings, the majority of healthcare providers being untrained in 
PrEP provision, limited data about potential adverse effects from long-term use of tenofavir-
emtricitabine, high costs of PrEP medication and stigma. 231 
 
PrEP has not been around long enough to fully appreciate the long term effects. There is 
not enough research to show that a person can use this drug for an extended period of time 
safely. There are concerns that PrEP may lead to more opportunities for drug resistant strains of 
HIV to develop. 232 New diseases are discovered all the time. 50 years ago AIDS did not exist 
and when it was discovered, it would be years before testing could be done and even longer for 
treatment. If patients do not adhere to the recommendations to use PrEP properly with the 
combination of condoms, then we may face another public health epidemic with a new disease 
that may be transmitted sexually. 
Not everyone is educated on the use of PrEP. Not only do the patients that are being 
prescribed need the education but also their sexual partners. If a person tells his partner that he is 
on PrEP, there is no indication or proof that he has been taking the recommended dose or that he 
is continuing to be tested for HIV as the guidelines recommend. The public needs to to know 
what to ask and they need to be educated about the consequences of non-adherence. 
Education was an important element in fighting the spread of AIDS. Today there is a lack 
of education, and media coverage is almost non existent about HIV and AIDS. There needs to be 
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constant training and education on AIDS and HIV and the use of treatment therapies and 
prevention. 
If society continues to disregard the requirements to use PrEP with condoms, then society 
will face another epidemic when a new deadly disease is discovered and history will 
unfortunately repeat itself.  PrEP is a miracle drug that has saved lives and changed how the 
world thinks about HIV.  There needs to be modifications to how the medicine is prescribed and 
there needs to be better education and information about adherence to the drug. 
